Morepen Adds ‘Blockbusters’ To API Portfolio
The Indian Firm Is Eyeing A Move Up The Value Chain
India’s Morepen Laboratories has added two “blockbuster drugs” and one niche product to its API portfolio for sale in its domestic and global markets as it looks to move up the value chain following approval for its in-house R&D center.
You may also be interested in...
INFOGRAPHIC: A relatively small number of relatively costly drugs account for a sizable proportion of pharma industry revenues. But what are its biggest golden eggs, how reliant are companies on those products, and how has the situation evolved over time?
Morepen has received US Food and Drug Administration (FDA) approval for both of its active pharmaceutical ingredient (API) manufacturing facilities in Himachal Pradesh, India. As a result, the site in Baddhi is now able to supply atorvastatin calcium to the US, while the Masulkhana plant can manufacture montelukast sodium.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.